Global healthcare leader acquires microcap psychedelic stock

Otsuka Pharmaceutical has acquired Mindset Pharma, a microcap psychedelic stock developing drugs for psychiatric and neurological disorders.

Cybin gears up to acquire Small Pharma Inc.

Cybin (NEO:CYBN) is gearing up to acquire Small Pharma Inc. (TSXV:DMT) to create the psychedelics industry's largest DMT program.

World’s first psychedelic microdosing home trials ready for Phase 2

MindBio Therapeutics (CSE:MBIO) received the first batch of its drug for take-home use in Phase 2 psychedelic microdosing clinical trials.

The biotech/pharma team set up to enhance psychedelic therapeutics

Clearmind Medicine (CSE:CMND) has agreed to collaborate on product development with pharmaceutical and consumer products company CTS Ltd.

Red Light Holland starts stability testing for psilocybin capsules

Red Light Holland (CSE:TRIP) begins stability testing for its psilocybin microdosing capsules The capsules were developed...

Optimi Health to supply MDMA for therapist experiential training program

Optimi Health (OPTI) will manufacture and supply MDMA for the program set to take place later...

Psychedelics stock’s LSD clinical trial reports sleep quality breakthrough

Psychedelics stock MindBio Therapeutics (CSE:MBIO) made a major discovery from sleep data from its LSD-microdosing trials...

Psychedelics company begins phase 3 psilocybin study for depression

Psychedelics company Numinus Wellness has initiated a study on COMP360 psilocybin for treatment-resistant depression (TRD) as...
MindBio Therapeutics - Chief Executive, Justin Hanka.

Psychedelics stock moving forward with pioneering LSD clinical trial

Psychedelics stock MindBio Therapeutics receives ethics approval for its Phase 2a take-home LSD microdosing clinical trial...

Clearmind (CSE:CMND) approved to conduct clinical trial on alcohol use disorder

Clearmind (CMND) received approval for its CMND-100 compound to treat alcohol use disorder at Israel’s IMCA...

Optimi Health (CSE:OPTI) granted a Natural Health Product Site Licence by Health Canada

Optimi Health (OPTI) has received a Natural Health Product Site Licence by Health Canada The licence also...
The Market Herald Video

Psyched Wellness (CSE:PSYC) and HealingMaps to offer Amanita Muscaria tincture, Calm, to HealingMaps universe

This is sponsored content issued on behalf of Psyched Wellness, please see full disclaimer here.
MindBio Therapeutics - Chief Executive, Justin Hanka.

MindBio Therapeutics (CSE:MBIO) begins trading on the CSE

MindBio Therapeutics (MBIO) is now trading on the Canadian Securities Exchange MindBio is among a select...

Optimi Health (CSE:OPTI) notches C$1.2 million psilocybin supply agreement

Optimi Health Corp. (OPTI) enters into a C$1.2 million agreement to focus on developing mushroom-based therapeutic...

Clearmind (CSE:CMND) signs supply agreement for its upcoming clinical trial

Clearmind (CMND) has signed an agreement with IMP Clinical Supply Services IMP will be responsible for...

Nova Mentis (CSE:NOVA) enters mRNA AI diagnostics business

Nova Mentis’ (NOVA) wholly owned subsidiary, Pilz Bioscience Inc. will change its name to to SwabAi...
Psyched Wellness

Psyched Wellness (CSE:PSYC) lists Calm in all locations of Good Earth Markets

Psyched (PSYC) announced that Calm continues to expand within brick and mortar retailers by listing at...

Red Light Holland (CSE:TRIP) notches certificate of analysis for psilocybin truffles

Red Light Holland (TRIP) notches certificate of analysis for psilocybin truffles The analysis was done by...

Clearmind (CSE:CMND) expands portfolio with patent application to treat depression

Clearmind (CMND) has filed a patent application to protect its combination to treat depression The company...